Regulus Therapeutics Inc. (NASDAQ:RGLS) Rating Changes as of Jun 27, 2018

June 27, 2018 - By Gwen Gough

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.11. That’s change of 0.05, from 2017Q4’s 1.16. 8 investors sold all, 10 reduced holdings as Regulus Therapeutics Inc. ratio dropped. 11 grew positions while 9 funds took positions. Funds hold 50.71 million shares thus 4.62% less from 2017Q4’s 53.17 million shares.
Bvf Il holds 1.02% or 13.97 million shs in its capital. Vanguard Group reported 2.78 million shs. The Illinois-based Drw Secs Limited has invested 0.01% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Barclays Public Limited Company reported 91 shs. Alpine Mgmt Lc stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Moreover, Bourgeon Mngmt Limited Liability Company has 0.01% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 13,304 shs. Panagora Asset Mngmt invested in 0% or 79,080 shs. Macquarie Group Incorporated reported 0% stake. Royal Bancorporation Of Canada has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Hightower Advsrs Ltd Co holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 22,475 shs. Fincl Bank Of Mellon Corp has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Guggenheim Capital Ltd Liability Com invested in 0% or 26,025 shs. Northern Trust Corp reported 187,492 shs. Utd Automobile Association reported 0% stake. Virtu Finance Ltd owns 78,587 shs.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus Therapeutics (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since January 5, 2018 according to StockzIntelligence Inc Regulus Therapeutics has 7 analyst reports. On Monday, March 12 the firm earned “Buy” rating by Wedbush. On Tuesday, March 27 the rating was initiated by FBR Capital with “Hold”. The company rating was maintained by Wedbush on Thursday, May 17. On Thursday, March 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Market Perform” rating by BMO Capital Markets. On Thursday, February 8 the rating was maintained by Wedbush with “Buy”. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

RGLS hit $0.66 during the last trading session after $0 change.It’s downtrending since June 27, 2017 and is 45.33% down. RGLS underperformed by 57.90% the S&P500.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $68.85 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

There’s a substantial Regulus Therapeutics Inc. (NASDAQ:RGLS) news published by It’s an item titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: